This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
by Zacks Equity Research
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Top Research Reports for JPMorgan, American Express & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), American Express (AXP) and FedEx (FDX).
5 Reasons Why Investors Should Bet on Merck (MRK) Stock
by Zacks Equity Research
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's Novel Diabetes Candidate Shows Promise in Phase II
by Zacks Equity Research
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View
by Swarup Gupta
The index advanced strongly this week before suffering a sharp decline on Thursday.
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC
by Zacks Equity Research
Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
Roche Gets FDA Approval for New Formulation of Asthma Drug
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer
by Zacks Equity Research
Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.
Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
by Zacks Equity Research
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
by Zacks Equity Research
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Company News For Sep 26, 2018
by Zacks Equity Research
Companies in the news are: FDS, SONC, AZN and EVHC
AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
NVS vs. AZN: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. AZN: Which Stock Is the Better Value Option?
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
by Zacks Equity Research
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
by Zacks Equity Research
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.